Luye Pharma Group Ltd.

SEHK:2186 Rapport sur les actions

Capitalisation boursière : HK$10.8b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Luye Pharma Group Gestion

Gestion contrôle des critères 3/4

We currently do not have sufficient information about the CEO.

Informations clés

Dian Bo Liu

Directeur général

CN¥4.2m

Rémunération totale

Pourcentage du salaire du PDG75.1%
Durée du mandat du directeur général21.1yrs
Propriété du PDGn/a
Durée moyenne d'occupation des postes de direction12.6yrs
Durée moyenne du mandat des membres du conseil d'administration10.2yrs

Mises à jour récentes de la gestion

We Discuss Why Luye Pharma Group Ltd.'s (HKG:2186) CEO Compensation May Be Closely Reviewed

May 21
We Discuss Why Luye Pharma Group Ltd.'s (HKG:2186) CEO Compensation May Be Closely Reviewed

Recent updates

Luye Pharma Group Ltd.'s (HKG:2186) Earnings Haven't Escaped The Attention Of Investors

Jun 19
Luye Pharma Group Ltd.'s (HKG:2186) Earnings Haven't Escaped The Attention Of Investors

We Discuss Why Luye Pharma Group Ltd.'s (HKG:2186) CEO Compensation May Be Closely Reviewed

May 21
We Discuss Why Luye Pharma Group Ltd.'s (HKG:2186) CEO Compensation May Be Closely Reviewed

Here's Why Luye Pharma Group (HKG:2186) Has A Meaningful Debt Burden

Apr 26
Here's Why Luye Pharma Group (HKG:2186) Has A Meaningful Debt Burden

Is Luye Pharma Group Ltd. (HKG:2186) Trading At A 27% Discount?

Feb 29
Is Luye Pharma Group Ltd. (HKG:2186) Trading At A 27% Discount?

Some Confidence Is Lacking In Luye Pharma Group Ltd.'s (HKG:2186) P/S

Jan 09
Some Confidence Is Lacking In Luye Pharma Group Ltd.'s (HKG:2186) P/S

Luye Pharma Group (HKG:2186) Takes On Some Risk With Its Use Of Debt

Dec 19
Luye Pharma Group (HKG:2186) Takes On Some Risk With Its Use Of Debt

A Look At The Fair Value Of Luye Pharma Group Ltd. (HKG:2186)

Nov 24
A Look At The Fair Value Of Luye Pharma Group Ltd. (HKG:2186)

Is Luye Pharma Group (HKG:2186) A Risky Investment?

Sep 12
Is Luye Pharma Group (HKG:2186) A Risky Investment?

Luye Pharma Group Ltd.'s (HKG:2186) Intrinsic Value Is Potentially 20% Below Its Share Price

Aug 17
Luye Pharma Group Ltd.'s (HKG:2186) Intrinsic Value Is Potentially 20% Below Its Share Price

Is Luye Pharma Group (HKG:2186) Using Too Much Debt?

May 10
Is Luye Pharma Group (HKG:2186) Using Too Much Debt?

We Think Luye Pharma Group (HKG:2186) Is Taking Some Risk With Its Debt

Sep 20
We Think Luye Pharma Group (HKG:2186) Is Taking Some Risk With Its Debt

Time To Worry? Analysts Just Downgraded Their Luye Pharma Group Ltd. (HKG:2186) Outlook

Apr 06
Time To Worry? Analysts Just Downgraded Their Luye Pharma Group Ltd. (HKG:2186) Outlook

Luye Pharma Group's (HKG:2186) Shareholders Are Down 31% On Their Shares

Mar 17
Luye Pharma Group's (HKG:2186) Shareholders Are Down 31% On Their Shares

A Closer Look At Luye Pharma Group Ltd.'s (HKG:2186) Impressive ROE

Feb 19
A Closer Look At Luye Pharma Group Ltd.'s (HKG:2186) Impressive ROE

Analyse de la rémunération des PDG

Comment la rémunération de Dian Bo Liu a-t-elle évolué par rapport aux bénéfices de Luye Pharma Group?
DateRémunération totaleSalaireBénéfices de l'entreprise
Dec 31 2023CN¥4mCN¥3m

CN¥533m

Sep 30 2023n/an/a

CN¥495m

Jun 30 2023n/an/a

CN¥458m

Mar 31 2023n/an/a

CN¥531m

Dec 31 2022CN¥3mCN¥3m

CN¥605m

Sep 30 2022n/an/a

CN¥190m

Jun 30 2022n/an/a

-CN¥224m

Mar 31 2022n/an/a

-CN¥179m

Dec 31 2021CN¥4mCN¥3m

-CN¥134m

Sep 30 2021n/an/a

CN¥210m

Jun 30 2021n/an/a

CN¥554m

Mar 31 2021n/an/a

CN¥630m

Dec 31 2020CN¥5mCN¥4m

CN¥707m

Sep 30 2020n/an/a

CN¥955m

Jun 30 2020n/an/a

CN¥1b

Mar 31 2020n/an/a

CN¥1b

Dec 31 2019CN¥4mCN¥3m

CN¥1b

Sep 30 2019n/an/a

CN¥1b

Jun 30 2019n/an/a

CN¥1b

Mar 31 2019n/an/a

CN¥1b

Dec 31 2018CN¥4mCN¥3m

CN¥1b

Sep 30 2018n/an/a

CN¥1b

Jun 30 2018n/an/a

CN¥1b

Mar 31 2018n/an/a

CN¥1b

Dec 31 2017CN¥4mCN¥3m

CN¥981m

Rémunération vs marché: Dian Bo's total compensation ($USD585.65K) is about average for companies of similar size in the Hong Kong market ($USD629.60K).

Rémunération et revenus: Dian Bo's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

PDG

Dian Bo Liu (58 yo)

21.1yrs

Titularisation

CN¥4,180,000

Compensation

Mr. Dian Bo Liu is a Co-Founder of Luye Pharma Group Ltd. in 1994 and serves as its Head of Corporate Directions & Strategies and has been its Chief Executive Officer since July 2003. Mr. Liu is responsibl...

Équipe de direction

NomPositionTitularisationCompensationPropriété
Dian Bo Liu
Co-Founder21.1yrsCN¥4.18mpas de données
Rong Bing Yang
Co-Founder & Vice Executive Chairman21.1yrsCN¥3.09mpas de données
Hui Xian Yuan
Co-Founder & Executive Directorno dataCN¥1.46mpas de données
Yuan Yuan Zhu
Executive Directorno dataCN¥1.50mpas de données
Yuan Chong Liu
Chief Financial Officer12.6yrspas de donnéespas de données
Mei Yi Lee
Company Secretary3.7yrspas de donnéespas de données

12.6yrs

Durée moyenne de l'emploi

58yo

Âge moyen

Gestion expérimentée: 2186's management team is seasoned and experienced (12.6 years average tenure).

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Dian Bo Liu
Co-Founder21.1yrsCN¥4.18mpas de données
Rong Bing Yang
Co-Founder & Vice Executive Chairman21.1yrsCN¥3.09mpas de données
Hui Xian Yuan
Co-Founder & Executive Director21.1yrsCN¥1.46mpas de données
Yuan Yuan Zhu
Executive Director10.4yrsCN¥1.50mpas de données
Yuk Lam Lo
Independent Non-Executive Director10.2yrsCN¥269.00kpas de données
Man Kit Leung
Independent Non-Executive Director10.2yrsCN¥322.00kpas de données
Rui Lin Song
Non-Executive Director7.4yrsCN¥269.00kpas de données
Sze Chung Choy
Independent Non-Executive Director10.2yrsCN¥269.00kpas de données
Huaqiao Zhang
Independent Non-Executive Director10.2yrsCN¥269.00kpas de données
Dong Lyu
Non-Executive Directorless than a yearpas de donnéespas de données
Lian Xia
Independent Non-Executive Director1.3yrsCN¥162.00kpas de données

10.2yrs

Durée moyenne de l'emploi

61yo

Âge moyen

Conseil d'administration expérimenté: 2186's board of directors are seasoned and experienced ( 10.2 years average tenure).